Tirzepatide reduces weight more than semaglutide in head-to-head trial of patients without diabetes
The findings were robust, said endocrinologist Professor Gary Wittert.
Tirzepatide leads to greater weight loss than semaglutide in adults with obesity but without type 2 diabetes, a head-to-head trial suggests.
Published in the New England Journal of Medicine, the SURMOUNT-5 trial involved 751 participants randomly assigned to the maximum tolerated dose of tirzepatide (10mg or 15mg) or semaglutide (1.7mg or 2.4mg) and treated for 72 weeks.
